comprehensive investigation was performed to identify new benzodiazepine (BZD) derivatives as potent and selective human lysine deacetylase inhibitors (hKDACis). A total of 108 BZD compounds were designed, synthesized and from that 104 compounds were biologically evaluated against human lysine deacetylases (hKDACs) 1, 3 and 8 (class I) and 6 (class IIb). The most active compounds showed mid-nanomolar potencies
进行了全面的调查,以确定新的苯二氮卓(
BZD)衍
生物作为有效的和选择性的人赖
氨酸脱乙酰基酶
抑制剂(hK
DACis)。总共设计,合成了108种
BZD化合物,并从这104种化合物中分别针对人赖
氨酸脱乙酰基酶(hK
DAC)1、3和8(I类)和6(IIb类)进行了
生物学评估。活性最高的化合物对hK
DACs 1、3和6表现出中等纳摩尔效价,对hK
DAC8的微摩尔活性,而一种有前途的化合物(6q)显示出在不同酶同工型中对hK
DAC3的选择性。生成了hK
DAC6同源性模型,该模型通过分子动力学模拟进行了改进,并进行了分子对接研究,以使主要的
配体-残基相互作用合理化,并定义了结构-活性-关系。实验结果证实了在追求hK
DAC同工型选择性抑制时,苯并二氮杂moiety部分作为封端基是有用的,这表明在设计新的hK
DACis时可以继续使用。